Association between HCV infection and diabetes has been widely postulated. Little is known about the impact of direct acting antiviral agents (DAAs) on glycemic control. Aim of our study was to evaluate the glycemic control modifications in a case series of HCV+ diabetic population receiving DAAs. We retrospectively evaluated 149 HCV+ patients in two different institutions affiliated to the Sapienza University: Policlinico Umberto I of Rome and Ospedale Santa Maria Goretti of Latina. We were able to identify 29 patients with T2DM (19% of total population) who were receiving different IFN-free regimens. During-treatment fasting glucose values were available for 21 patients and analysis showed a statistically significant reduction (p=0,007), the reduction mean value was -52,86 mg/dl. An A1C value during treatment (week 4 or week 8 or week 12) was available for 10 patients and the analysis showed a statistically significant reduction (p=0,021) with a reduction mean value of -1,95%. 6 patients (23%) needed to reduce hypoglycemic drugs, 8 of 10 patients showed reduction of A1C, 14 of 21 patients (67%) showed reduced FG during treatment. FG and A1C reductions values were independent from which DAA was present in the regimen, HCV genotype, BMI and HIV status. In order to avoid hypoglycemic events, diabetic patients undergoing DAAs should be closely monitorized for reduction of hypoglycemic drugs. Furthermore, diabetes could be considered, in our opinion, as an element to prioritize treatment in those patients with no apparent liver disease.

Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents / Pavone, Paolo; Tieghi, Tiziana; D'Ettorre, G.; Lichtner, Miriam; Marocco, Raffaella; Mezzaroma, Ivano; Passavanti, G.; Vittozzi, Pietro; Mastroianni, Claudio Maria; Vullo, Vincenzo. - In: CLINICAL MICROBIOLOGY AND INFECTION. - ISSN 1198-743X. - ELETTRONICO. - 22:5(2016), pp. 1-3. [10.1016/j.cmi.2015.12.030]

Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents

pavone, paolo
Primo
Conceptualization
;
TIEGHI, TIZIANA
Secondo
;
D'Ettorre, G.;LICHTNER, Miriam;MAROCCO, RAFFAELLA;MEZZAROMA, Ivano;VITTOZZI, PIETRO;MASTROIANNI, Claudio Maria
Penultimo
;
VULLO, Vincenzo
Ultimo
2016

Abstract

Association between HCV infection and diabetes has been widely postulated. Little is known about the impact of direct acting antiviral agents (DAAs) on glycemic control. Aim of our study was to evaluate the glycemic control modifications in a case series of HCV+ diabetic population receiving DAAs. We retrospectively evaluated 149 HCV+ patients in two different institutions affiliated to the Sapienza University: Policlinico Umberto I of Rome and Ospedale Santa Maria Goretti of Latina. We were able to identify 29 patients with T2DM (19% of total population) who were receiving different IFN-free regimens. During-treatment fasting glucose values were available for 21 patients and analysis showed a statistically significant reduction (p=0,007), the reduction mean value was -52,86 mg/dl. An A1C value during treatment (week 4 or week 8 or week 12) was available for 10 patients and the analysis showed a statistically significant reduction (p=0,021) with a reduction mean value of -1,95%. 6 patients (23%) needed to reduce hypoglycemic drugs, 8 of 10 patients showed reduction of A1C, 14 of 21 patients (67%) showed reduced FG during treatment. FG and A1C reductions values were independent from which DAA was present in the regimen, HCV genotype, BMI and HIV status. In order to avoid hypoglycemic events, diabetic patients undergoing DAAs should be closely monitorized for reduction of hypoglycemic drugs. Furthermore, diabetes could be considered, in our opinion, as an element to prioritize treatment in those patients with no apparent liver disease.
File allegati a questo prodotto
File Dimensione Formato  
Pavone_Rapid_2016.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 109.37 kB
Formato Adobe PDF
109.37 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/867989
Citazioni
  • ???jsp.display-item.citation.pmc??? 28
  • Scopus 62
  • ???jsp.display-item.citation.isi??? 61
social impact